Alzheimer's: Positive Phase 1 Data For ANAVEX 2-73

Share this content:
Alzheimer's: positive Phase 1 data for ANAVEX 2-73
Alzheimer's: positive Phase 1 data for ANAVEX 2-73
Anavex Life Sciences Corp. has announced full data results from the Phase 1 clinical trial of ANAVEX 2-73, the Company's lead investigational oral treatment for Alzheimer's, which has shown potential in preclinical studies to prevent, halt and/or reverse the course of the disease.
READ FULL ARTICLE From Medical News Today
Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters


is free, fast, and customized just for you!

Already a member?

Sign In Now »